©2020-2032 All Rights
Reserved. Online Journal
of Bioinformatics . You
may not store these pages in any form except for your own personal use. All
other usage or distribution is illegal under international copyright
treaties. Permission to use any of these pages in any
other way besides the before mentioned must be gained in writing from the
publisher. This article is exclusively copyrighted in its entirety
to OJB publications. This article may be copied once but may not be, reproduced
or re-transmitted without the express permission of the editors. This journal satisfies the refereeing requirements (DEST) for the
Higher Education Research Data Collection (Australia). Linking:To link to this page or any pages linking to this
page you must link directly to this page only here rather than put up your own
page.
OJBTM
Online
Journal of Bioinformatics©
Volume 21(2): 168-181, 2020.
In silico multi-epitope
severe fever thrombocytopenia syndrome vaccine targets virus membrane
glycoprotein.
Ramya Bandarupalli1, Bhavana
Kasaraneni1, Chandana Madala1, Lahari Paladugu1, Kanaka Durga
Devi Nelluri2*
1Department(s) of Pharmacy Practice, 2Pharmaceutics
and Biotechnology, KVSR Siddhartha College of Pharmaceutical Sciences,
Vijayawada, India. *Corresponding
Author: Dr.Nelluri Kanaka Durga
Devi,
ABSTRACT
Bandarupalli R, Kasaraneni B, Madala
C, Paladugu L, Devi Nelluri
KD., In silico multi-epitope severe fever thrombocytopenia syndrome vaccine
targets virus membrane glycoprotein, Onl J Bioinform., 21(2): 168-181,
2020. Thrombocytopenia
syndrome virus (SFTSV) can cause ~10-30% mortality in humans currently with no
vaccine or drugs for treatment. We describe an In silico multi-epitope vaccine targeting SFTSV membrane glycoprotein
polyprotein to predict B and T-cell epitopes for immunogenicity, allergenicity, toxicity and conservancy. Epitopes were
screened by docking with HLA alleles to generate highest immune response. The
3D model vaccine was docked with Toll-like receptor-8 by molecular dynamic
simulations. Further codon adaptation of vaccine sequence was cloned in silico in plasmid pIB2 vector to
ensure expression efficiency at production. Results need to be supported in vitro and in vivo for efficacy and safety.
KEYWORDS: SFTSV;
Multi-epitope vaccine; membrane glycoprotein polyprotein; Immuno-informatics;
Vaccine design.
FULL-TEXT (SUBSCRIBE OR
PURCHASE TITLE)